Completed × Has results × Lymphoma, Large B-Cell, Diffuse × Clear all RICER
Phase 1/2 Completed
18 enrolled 15 charts
BELINDA
Phase 3 Completed
330 enrolled 10 charts
INCA
Phase 2 Completed
129 enrolled 7 charts
Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib
Phase 2 Completed
65 enrolled 14 charts
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
Phase 1/2 Completed
55 enrolled 17 charts
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
Phase 1/2 Completed
97 enrolled 43 charts
Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL
Phase 2 Completed
82 enrolled 20 charts
A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)
Phase 2 Completed
87 enrolled 19 charts
EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection
Phase 2 Completed
68 enrolled 24 charts
POLARGO
Phase 3 Completed
270 enrolled 36 charts
ZUMA-7
Phase 3 Completed
359 enrolled 27 charts
Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab
Phase 1/2 Completed
53 enrolled 17 charts
FRAIL-06
Phase 2 Completed
67 enrolled 11 charts
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
Phase 3 Completed
700 enrolled 21 charts
A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)
Phase 2 Completed
60 enrolled 15 charts
BEB
Phase 2 Completed
108 enrolled 15 charts
B-MIND
Phase 2/3 Completed
453 enrolled 29 charts
New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement
Phase 2 Completed
79 enrolled 26 charts
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
Phase 2 Completed
348 enrolled 15 charts
Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma
Phase 1 Completed
12 enrolled 13 charts
S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma
Phase 2 Completed
159 enrolled 21 charts
Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
Phase 1 Completed
34 enrolled 14 charts
Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Phase 1 Completed
66 enrolled 52 charts
Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma
Phase 1/2 Completed
11 enrolled 12 charts
Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 1/2 Completed
19 enrolled 12 charts
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
Phase 1 Completed
49 enrolled 32 charts
Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting
Phase 4 Completed
25 enrolled 17 charts
Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma
Phase 2 Completed
12 enrolled 13 charts
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)
Phase 2 Completed
104 enrolled 29 charts
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels
Phase 1 Completed
42 enrolled 39 charts
SEARCH
Phase 2 Completed
60 enrolled 9 charts
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Phase 3 Completed
838 enrolled 16 charts
Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma
Phase 2 Completed
22 enrolled 15 charts
Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1â„¢
Phase 3 Completed
256 enrolled 9 charts
Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma
Phase 1/2 Completed
138 enrolled 16 charts
TRANSCENDWORLD
Phase 2 Completed
113 enrolled 35 charts
Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma
Phase 1 Completed
21 enrolled 11 charts
Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma
Phase 2 Completed
41 enrolled 15 charts
BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)
Phase 2 Completed
41 enrolled 25 charts
HARBOUR
Phase 1 Completed
31 enrolled 29 charts
Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL
Phase 1 Completed
66 enrolled 21 charts
Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT
Phase 2 Completed
64 enrolled 17 charts
A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma
Phase 1/2 Completed
59 enrolled 11 charts
FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL
Phase 1 Completed
7 enrolled 12 charts
BIANCA
Phase 2 Completed
34 enrolled 19 charts
AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders
Phase NA Completed
10 enrolled 11 charts
Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL
Phase 2 Completed
100 enrolled 21 charts
ZUMA-1
Phase 1/2 Completed
307 enrolled 41 charts
RAPID
Phase 2 Completed
124 enrolled 13 charts
Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma
Phase 1/2 Completed
48 enrolled 18 charts